A novel vaccine for mantle cell lymphoma based on targeting cyclin D1 to dendritic cells via CD40

Journal of Hematology and Oncology

Volumn 8, Issue 1, 2015, Pages

  Chen, Jingtao ^a,b   Zurawski, Gerard ^b   Zurawski, Sandy ^b   Wang, Zhiqing ^b   Akagawa, Keiko ^b   Oh, Sangkon ^b   Hideki, Ueno ^b   Fay, Joseph ^b   Banchereau, Jacques ^b,c   Song, Wenru ^b,d   Palucka, A Karolina ^b,c  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^c JACKSON LABORATORY   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Cyclin D1; Dendritic cells; Mantle cell lymphoma; Tumor antigen; Vaccine

Indexed keywords

CD40 ANTIGEN; CYCLIN D1; DENDRITIC CELL VACCINE; GAMMA INTERFERON; HYBRID PROTEIN; RECOMBINANT VACCINE; TUMOR ANTIGEN; CANCER VACCINE; CCND1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE RELEASE; DENDRITIC CELL; DRUG TARGETING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; INVESTIGATIVE PROCEDURES; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MIDDLE AGED; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MOLECULARLY TARGETED THERAPY; PROCEDURES; CELL KILLING; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; MONOCYTE; PROTEIN TARGETING; TUMOR CELL;

AGED; ANTIGENS, CD40; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CYCLIN D1; DENDRITIC CELLS; HUMANS; IN VITRO TECHNIQUES; LYMPHOCYTE ACTIVATION; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; RECOMBINANT FUSION PROTEINS; VACCINES, SYNTHETIC;

EID: 85018115359     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-015-0131-7     Document Type: Article

References (56)

1. Foran JM, Cunningham D, Coiffier B, Solal-Celigny P, Reyes F, Ghielmini M, et al. Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann Oncol. 2000;11 Suppl 1:117-21.
2. Chen Y, Wang M, Romaguera J. Current regimens and novel agents for mantle cell lymphoma. Br J Haematol. 2014.
3. Dreyling, M., et al. Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma (MCL) - summary of the 12 annual conference of the EUROPEAN MCL NETWORK. Leuk Lymphoma, 2014. p. 1-26.
4. Williams ME, Dreyling MH, Kahl BS, Leonard JP, O'Connor OA, Press OW, et al. Mantle cell lymphoma: report of the 2009 mantle cell lymphoma consortium workshop. Leuk Lymphoma. 2010;51(3):390-8.
5. Dietrich S et al. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol. 2014;25(5):1053-8.
6. Qi CF, Xiang S, Shin MS, Hao X, Lee CH, Zhou JX, et al. Expression of the cyclin-dependent kinase inhibitor p27 and its deregulation in mouse B cell lymphomas. Leuk Res. 2006;30(2):153-63.
7. Jares P, Campo E. Advances in the understanding of mantle cell lymphoma. Br J Haematol. 2008;142(2):149-65.
8. Salaverria I, Royo C, Carvajal-Cuenca A, Clot G, Navarro A, Valera A, et al. CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma. Blood. 2013;121(8):1394-402.
9. Chuang SS, Huang WT, Hsieh PP, Tseng HH, Campo E, Colomer D, et al. Mantle cell lymphoma in Taiwan: clinicopathological and molecular study of 21 cases including one cyclin D1-negative tumor expressing cyclin D2. Pathol Int. 2006;56(8):440-8.
10. Fu K, Weisenburger DD, Greiner TC, Dave S, Wright G, Rosenwald A, et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood. 2005;106(13):4315-21.
11. Seto M. Cyclin D1-negative mantle cell lymphoma. Blood. 2013;121(8):1249-50.
12. Bacher U et al. Cyclin D1 (CCND1) messenger RNA expression as assessed by real-time PCR contributes to diagnosis and follow-up control in patients with mantle cell lymphoma. Exp Hematol. 2013
13. Soverini S et al. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Blood. 2003;102(5):1588-94.
14. Sauerbrey A, Häfer R, Zintl F, Volm M. Analysis of cyclin D1 in de novo and relapsed childhood acute lymphoblastic leukemia. Anticancer Res. 1999;19(1B):645-9.
15. Bosch F, Campo E, Jares P, Pittaluga S, Muñoz J, Nayach I, et al. Increased expression of the PRAD-1/CCND1 gene in hairy cell leukaemia. Br J Haematol. 1995;91(4):1025-30.
16. Arber N et al. Increased expression of the cyclin D1 gene in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev. 1996;5(6):457-9.
17. Arber N, Hibshoosh H, Moss SF, Sutter T, Zhang Y, Begg M, et al. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology. 1996;110(3):669-74.
18. Ratschiller D, Heighway J, Gugger M, Kappeler A, Pirnia F, Schmid RA, et al. Cyclin D1 overexpression in bronchial epithelia of patients with lung cancer is associated with smoking and predicts survival. J Clin Oncol. 2003;21(11):2085-93.
19. Weinschenk T, Gouttefangeas C, Schirle M, Obermayr F, Walter S, Schoor O, et al. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res. 2002;62(20):5818-27.
20. Gladden AB, Diehl JA. Location, location, location: the role of cyclin D1 nuclear localization in cancer. J Cell Biochem. 2005;96(5):906-13.
21. Gautschi O, Ratschiller D, Gugger M, Betticher DC, Heighway J. Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. Lung Cancer. 2007;55(1):1-14.
22. Dengjel J, Decker P, Schoor O, Altenberend F, Weinschenk T, Rammensee HG, et al. Identification of a naturally processed cyclin D1 T-helper epitope by a novel combination of HLA class II targeting and differential mass spectrometry. Eur J Immunol. 2004;34(12):3644-51.
23. Kondo E, Maecker B, Weihrauch MR, Wickenhauser C, Zeng W, Nadler LM, et al. Cyclin D1-specific cytotoxic T lymphocytes are present in the repertoire of cancer patients: implications for cancer immunotherapy. Clin Cancer Res. 2008;14(20):6574-9.
24. Dao T, Korontsvit T, Zakhaleva V, Haro K, Packin J, Scheinberg DA. Identification of a human cyclin D1-derived peptide that induces human cytotoxic CD4 T cells. PLoS One. 2009;4(8), e6730.
25. Armstrong MJ, Robins GG, Howdle PD. Recent advances in coeliac disease. Curr Opin Gastroenterol. 2009;25(2):100-9.
26. Wang M, Sun L, Qian J, Han X, Zhang L, Lin P, et al. Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy. Leukemia. 2009;23(7):1320-8.
27. Dougan, M, Dranoff G. The immune response to tumors. Curr Protoc Immunol. 2009. Chapter 20: p. Unit 20 11
28. Palucka AK, Ueno H, Fay JW, Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunol Rev. 2007;220:129-50.
29. Flacher V, Tripp CH, Stoitzner P, Haid B, Ebner S, Del Frari B, et al. Epidermal Langerhans cells rapidly capture and present antigens from C-type lectin-targeting antibodies deposited in the dermis. J Invest Dermatol. 2010;130(3):755-62.
30. Sancho D, Mourão-Sá D, Joffre OP, Schulz O, Rogers NC, Pennington DJ, et al. Tumor therapy in mice via antigen targeting to a novel DC-restricted C-type lectin. J Clin Invest. 2008;118(6):2098-110.
31. Birkholz K, Schwenkert M, Kellner C, Gross S, Fey G, Schuler-Thurner B, et al. Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation. Blood. 2010;116(13):2277-85.
32. Bozzacco L, Trumpfheller C, Siegal FP, Mehandru S, Markowitz M, Carrington M, et al. DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes. Proc Natl Acad Sci U S A. 2007;104(4):1289-94.
33. Klechevsky E, Flamar AL, Cao Y, Blanck JP, Liu M, O'Bar A, et al. Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR. Blood. 2010;116(10):1685-97.
34. Delneste Y, Magistrelli G, Gauchat J, Haeuw J, Aubry J, Nakamura K, et al. Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity. 2002;17(3):353-62.
35. Figdor CG, van Kooyk Y, Adema GJ. C-type lectin receptors on dendritic cells and Langerhans cells. Nat Rev Immunol. 2002;2(2):77-84.
36. Geijtenbeek TB, van Vliet SJ, Engering A, 't Hart BA, van Kooyk Y. Self- and nonself-recognition by C-type lectins on dendritic cells. Annu Rev Immunol. 2004;22:33-54.
37. Brown GD. Dectin-1: a signalling non-TLR pattern-recognition receptor. Nat Rev Immunol. 2006;6(1):33-43.
38. Singh J, Garber E, Van Vlijmen H, Karpusas M, Hsu YM, Zheng Z, et al. The role of polar interactions in the molecular recognition of CD40L with its receptor CD40. Protein Sci. 1998;7(5):1124-35.
39. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol. 2000;67(1):2-17.
40. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392(6673):245-52.
41. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med. 1996;184(2):747-52.
42. Xu H, Zhao G, Huang X, Ding Z, Wang J, Wang X, et al. CD40-expressing plasmid induces anti-CD40 antibody and enhances immune responses to DNA vaccination. J Gene Med. 2010;12(1):97-106.
43. Schjetne KW, Fredriksen AB, Bogen B. Delivery of antigen to CD40 induces protective immune responses against tumors. J Immunol. 2007;178(7):4169-76.
44. Flamar AL et al. Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells. AIDS. 2013.
45. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12(4):265-77.
46. Vigneron N, Stroobant V, Van den Eynde BJ, van der Bruggen P. Database of T cell-defined human tumor antigens: the 2013 update. Cancer Immun. 2013;13:15.
47. Uram JN, Black CM, Flynn E, Huang L, Armstrong TD, Jaffee EM. Nondominant CD8 T cells are active players in the vaccine-induced antitumor immune response. J Immunol. 2011;186(7):3847-57.
48. Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res. 1996;56(11):2479-83.
49. Noguchi M, Sasada T, Itoh K. Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine. Cancer Immunol Immunother. 2013;62(5):919-29.
50. Yamada A, Sasada T, Noguchi M, Itoh K. Next-generation peptide vaccines for advanced cancer. Cancer Sci. 2013;104(1):15-21.
51. Bonifaz L et al. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med. 2002;196(12):1627-38.
52. Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, Soares H, et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med. 2004;199(6):815-24.
53. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med. 2001;194(6):769-79.
54. Sadovnikova E, Jopling LA, Soo KS, Stauss HJ. Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules. Eur J Immunol. 1998;28(1):193-200.
55. Li D, Romain G, Flamar AL, Duluc D, Dullaers M, Li XH, et al. Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10-producing suppressive CD4+ T cells. J Exp Med. 2012;209(1):109-21.
56. Fan J, Hall P. On curve estimation by minimizing mean absolute deviation and its implications. Ann Stat. 1994;22(2):867-85.